Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Sparrow Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: Type 2 Diabetes; Cortisol Excess

Treatments: Drug: clofutriben; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07296484

SPI-62-CL-2006

Details and patient eligibility

About

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

Full description

CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.

The trial consists of two parts.

Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.

During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• From Screening 1

  • Age at least 18 years.

  • HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).

  • Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).

  • Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.

  • Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.

  • At least one of the following

    • ≥3 stable and adequate ADMs;
    • diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
    • hypertension requiring ≥2 adequately dosed AHMs;
    • adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
    • adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
    • evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
    • or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.

At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.

At Screening 2

• HbA1c ≥7.5% at Screening 2. At Day 1
• No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.

Exclusion criteria

• New-onset diabetes (onset <1 year in the past).

• Unwillingness to maintain with current glucose-lowering regimen during the trial.

• Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.

• Unwillingness to comply with CGM or other trial procedures.

• Investigator considers the patient will otherwise be unwilling or unable to complete the trial.

• Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.

• Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).

• Any of the following in medical history:

  • Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
  • A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
  • Hypersensitivity or severe reaction to dexamethasone;
  • Pheochromocytoma, or suspicion thereof;
  • Anorexia, or other eating disorder;
  • Glucocorticoid resistance;
  • Multiple sclerosis;
  • Significant hepatic impairment (e.g., Child-Pugh Class B or C);
  • Idiopathic thrombocytopenic purpura;
  • Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
  • Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
  • Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
  • Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
  • Any of the following in medication history:
  • Any of the excluded medications listed in Section 6.9;
  • Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
  • Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
  • Pregnancy (including a positive urine test) or current breast feeding.

From Screening 2

• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:

• wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
• a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
• supraclavicular/dorsocervical fat accumulation;
• irounding of the face (especially compared with prior photos);
• skin changes (violaceous striae, skin thinning, or excessive bruising);
• proximal muscle weakness on exam; or
• history of deep vein thrombosis/pulmonary embolism.
• Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
• Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
• Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
• Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
• Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
• Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
• Known hypersensitivity to clofutriben or to any of the product

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,500 participants in 5 patient groups, including a placebo group

Dose 1

Experimental group

Description:

clofutriben .2 mg oral tablet daily

Treatment:

Drug: clofutriben

Dose 2

Experimental group

Description:

clofutriben 2mg oral tablet daily

Treatment:

Drug: clofutriben

Dose 3

Experimental group

Description:

clofutriben 6mg oral tablet daily

Treatment:

Drug: clofutriben

Dose 4

Experimental group

Description:

clofutriben 12 mg oral tablet daily

Treatment:

Drug: clofutriben

placebo

Placebo Comparator group

Description:

placebo control oral tablet daily

Treatment:

Drug: Placebo